3',4',5,7-TETRAHYDROXYISOFLAVONE manufacturers
- Orobol
-
- $1.00 / 1KG
-
2025-12-12
- CAS:480-23-9
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 20000KG
|
| | 3',4',5,7-TETRAHYDROXYISOFLAVONE Basic information |
| Product Name: | 3',4',5,7-TETRAHYDROXYISOFLAVONE | | Synonyms: | OROBOL;3’,4’,5,7-tetrahydroxy-isoflavon;5,7,3’,4’-tetrahydroxyisoflavone;5,7-dihydroxy-3-(3,4-dihydroxyphenyl)-4h-1-benzopyran-4-on;5,7-dihydroxy-3-(3,4-dihydroxyphenyl)-4h-1-benzopyran-4-one;isoluteolin;3-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one;3'-Hydroxygenistein | | CAS: | 480-23-9 | | MF: | C15H10O6 | | MW: | 286.24 | | EINECS: | | | Product Categories: | Iso-Flavones | | Mol File: | 480-23-9.mol |  |
| | 3',4',5,7-TETRAHYDROXYISOFLAVONE Chemical Properties |
| Melting point | 270 °C | | Boiling point | 616.1±55.0 °C(Predicted) | | density | 1.654±0.06 g/cm3(Predicted) | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | pka | 6.37±0.20(Predicted) | | form | powder | | color | Yellow | | Cosmetics Ingredients Functions | ANTIOXIDANT |
| | 3',4',5,7-TETRAHYDROXYISOFLAVONE Usage And Synthesis |
| Uses | Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC50=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC50=3.46-5.27 μM for PI3K α/β/γ/K/δ)[1][2]. | | Definition | ChEBI: Orobol is a member of the class of 7-hydroxyisoflavones which consists of isoflavone substituted by hydroxy groups at positions 5, 7, 3' and 4'. It has been isolated from the mycelia of Cordyceps sinensis. It has a role as an anti-inflammatory agent, a radical scavenger, a plant metabolite and a fungal metabolite. It is functionally related to an isoflavone. | | in vivo | Orobol attenuates high fat diet-induced weight gain and lipid accumulation without affecting food intake in C57BL/6J mice[2]. | Animal Model: | HFD-induced obesity in C57BL/6J mice[2] | | Dosage: | 10mg/kg | | Administration: | Intragastrically; daily for 23 weeks | | Result: | Significantly reduced body weight by 17.3% compared to the HFD group.
|
| | target | PI3K | Caspase | Bcl-2/Bax | Calcium Channel | Antifection | Influenza virus | | References | [1] Kim MH, et al. Lipid Nanoparticles for Enhancing the Physicochemical Stability and Topical Skin Delivery of Orobol. Pharmaceutics. 2020;12(9):845. Published 2020 Sep 3. DOI:10.3390/pharmaceutics12090845 |
| | 3',4',5,7-TETRAHYDROXYISOFLAVONE Preparation Products And Raw materials |
|